Immunic, inc. announces $60.0 million oversubscribed private placement equity financing

New york , oct. 10, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux) ("immunic" or the "company"), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement (the "purchase agreement") with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock ("common stock") at a price of $4.35 per share, reflecting a 10% premium to the closing price on october 7, 2022 on nasdaq, and pre-funded warrants ("pre-funded warrants") to purchase up to an aggregate of 5,096,552 shares of common stock at a purchase price of $4.34 per pre-funded warrant share, through a private investment in public equity ("pipe") financing. the pre-funded warrants will have an exercise price of $0.01 per share of common stock, to be immediately exercisable and remain exercisable until exercised in full.
IMUX Ratings Summary
IMUX Quant Ranking